Advertisement

Topics

News about Biotechnology, Pharmaceutical and Healthcare

04:44 EDT 28th September 2016 | BioPortfolio

Latest news articles in the life-science, healthcare, medical device, biotechnology and pharmaceuticals sectors. 

Showing News Articles 1–25 of 25,000+

Tuesday 27th September 2016

Amgen’s Kyprolis Fails Key First-Line Multiple Myeloma Trial

THOUSAND OAKS, Calif., Sept. 27, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of KYPROLIS® (carfilzomib), melphalan and prednisone (KMP) versus Velcade® (bortezomib), melphalan and prednisone (VMP) for 54 weeks in patients with newly diagnosed multiple myeloma who were ineligible for hemat...

Report: Retailers want a piece of Korean beauty business

Gina AcostaDemand for Korean beauty products shows no signs of slowing down, according to a new report from Fast Company. read more

Former Shoppers Drug CEO passes

Michael JohnsenWhile David Bloom was CEO, Shoppers Drug Mart expanded from 400 to 837 stores, which included expansion into the U.S. market in Florida, sales quadrupled and earnings grew tenfold. read more

Shoppers Drug Mart's CEO at turn of the century dies at age 76

Michael JohnsenWhile David Bloom was CEO, Shoppers Drug Mart expanded from 400 to 837 stores, which included expansion into the U.S. market in Florida, sales quadrupled and earnings grew tenfold. read more

Prime Therapeutics Research Finds Nearly Half of Members Discontinue Costly RA Drug After One Year

ST. PAUL, MINN. – Sept. 27, 2016 – Prime Therapeutics LLC (Prime), a pharmacy benefit manager serving over 22 million members nationally, analyzed members’ use of rheumatoid arthritis (RA) drug tofacitinib (Xeljanz®) to find patterns and adherence behaviors. While use of the drug had been low (one member per 100,000 commercially insured members per month …

Self-regulation key to the future of health care tech

There are tools that work and there are tools that do not, but it’s important for the health care industry to decide what is required of these technologies for the future. And that means patients, physicians and developers working together. AMA Chief Executive Officer James L. Madara, MD, sat down with Matthew Holt of Health 2.0 at the annual conference yesterday to discuss the future of healt...

Overcoming gender obstacles in medicine

A lack of women in leadership positions, a gender pay gap, stereotypes and self-confidence all play a role in gender inequality in medicine. At the inaugural Women in Medicine Symposium, Vineet Arora, MD, detailed these issues and discussed how women could be more empowered in the medical field. Dr. Arora has spent most of her career in academic medicine and is currently assistant dean for Sch...

Kite Pharma’s CAR-T Therapy Demonstrates Positive Results in Lymphoma Study

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE) today announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). KTE-C19 met the primary endpoint of objective response rate (ORR), p<0.0001, with ORR of 76 percent, including 47 ...

Study: Site experience makes Amazon first with consumers in product search

Marianne WilsonA high-quality site experience makes Amazon the place where more than half (55%) of consumers go to first for products online.  read more

iMedicare launches nutrient depletion platform

David Salazar The company said it has developed an algorithm to identify drug-induced nutrient depletions in a pharmacy’s patients and recommend products for every situation.  read more

Perrigo gains distribution rights to Zephrex-D and Tarex meth-blocking technology

Michael JohnsenPerrigo plans to integrate the Tarex technology into certain of its store brand and retailer own label pseudoephedrine HCI products in the future and will immediately begin distribution of Zephrex D to its retail customers. read more

Upsher-Smith inks generic development, distribution agreement with Pharmathen

David Salazar Under the agreement, Pharmathen will develop, manufacture and supply a generic product in a $500 million category, and Upsher-Smith will submit the product for Food and Drug Administration approval and handle marketing and distributing in the United States as an Upsher-Smith generic.    read more

PSNC releases ‘spectacular’ data on pharmacy flu vaccinations

Community pharmacists in England have administered 150,000 influenza vaccinations in just over three weeks — nearly a quarter of the number achieved in the entire 2015-2016 campaign, according to statistics released by the Pharmaceutical Services Negotiating Committee.

Apotex makes generic Floxin Otic solution available

David SalazarApotex has re-entered the market with its generic Floxin Otic (ofloxacin otic solution, 0.3%). 

Irritable bowel syndrome drug given green light for use in Europe

The European Commission has granted a marketing authorisation to a first-in-class treatment for irritable bowel syndrome (IBS) called eluxadoline (Truberzi) for use in the EU.

Overwhelming Physician and Consumer Support Cited for 22nd Century’s “X-22” Very Low Nicotine Smoking Cessation Product

Tuesday, September 27th 2016 at 1:55pm UTC CLARENCE, N.Y.–(BUSINESS WIRE)– 22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced results from two separate independent surveys showing that strong consumer demand mirrors physicians’ willingness to prescribe the Company’s X-22 smoking cessation aid in development....

PERRIGO PRÉVOIT UN AVENIR BRILLANT POUR LE LABORATOIRE de la MER

Tuesday, September 27th 2016 at 1:42pm UTC DUBLIN–(BUSINESS WIRE)– Perrigo Company plc (NYSE : PRGO ; TASE) a annoncé ce jour la signature formelle entre le Laboratoire de la Mer (« LDLM ») et la Direction de Perrigo Branded Consumer Healthcare (« BCH ») de « l’accord de fin de conflit » reprenant les dispositions dont les parties étaient convenues mutuellement en jui...

Spineology Inc. Announces Unique TLIF Insertion Options for the Posterior Midline Approach ACT MediaLIF™

Tuesday, September 27th 2016 at 2:00pm UTC Combined technologies allow surgeons to reduce incision size and muscle trauma while using a direct posterior approach MINNEAPOLIS & ST. PAUL, Minn.–(BUSINESS WIRE)– Spineology Inc., the innovator in anatomy-conserving spine surgery, announced today the availability of multiple transforaminal lumbar interbody fusion (TLIF) technologies as ...

Augmenix Announces Positive SpaceOAR® Clinical Trial Results Demonstrating Superior Outcomes at 3-Years

Tuesday, September 27th 2016 at 2:09pm UTC Application of SpaceOAR hydrogel results in lower long-term rectal injury and higher patient quality of life scores WALTHAM, Mass.–(BUSINESS WIRE)– Today Augmenix, Inc. (http://www.spaceoar.com/), a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during...

Glytec Receives Three Additional Patent Notices of Allowance from USPTO for its Breakthrough Diabetes Technologies

Tuesday, September 27th 2016 at 2:18pm UTC The notices further validate Glytec’s position as a leader in advanced technologies and innovations for glycemic management. WALTHAM, Mass.–(BUSINESS WIRE)– Glytec today announces notices of allowance received from the United States Patent and Trademark Office (USPTO) for three patent applications directed toward its eGlycemic Management Sys...

Viamet to Present at the 25th European Academy of Dermatology and Venereology Congress

Tuesday, September 27th 2016 at 4:09pm UTC — Oral Presentation to Highlight Interim Phase 2b Data for VT-1161 in Onychomycosis — RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Viamet Pharmaceuticals, Inc. today announced that the company will present at the 25th European Academy of Dermatology and Venereology (EADV) Congress, September 28 – October 2, 2016, at the R...

ResQ Pharma Raises $725,000 and Scheduled to Meet FDA September 29th 2016

Tuesday, September 27th 2016 at 3:05pm UTC CHICAGO–(BUSINESS WIRE)– ResQ Pharma, Inc., a biopharmaceutical company focused on commercializing LipidRescue™ Therapy (LRT), which is a treatment for various drug overdoses and poisonings, announces the completion of a second seed-round of equity financing of $725,000.00. This financing brings their total seed financing to $1,050,000.00. T...

Ipsen annonce la présentation de données sur le cabozantinib (Cabometyx™), le lanréotide (Somatuline® Autogel®) et le telotristat éthyle* lors du congrès 2016 de l’European Society for Medical Oncology (ESMO)

Tuesday, September 27th 2016 at 4:00pm UTC PARIS–(BUSINESS WIRE)– class= »bwalignl »> Regulatory News: Ipsen (Euronext : IPN ; ADR : IPSEY), groupe pharmaceutique de spécialité international, a annoncé aujourd’hui que Cabometyx™ (cabozantinib), Somatuline® Autogel® (lanréotide) et le telotristat éthyle (*auparavant appelé telotristat etiprate) feront...

Virtual Tumor Board Initiative to Offer Greater Transparency in Brain Tumor Treatment Options

Tuesday, September 27th 2016 at 3:01pm UTC Henry Ford Health System and Synaptive Medical planning to make personalized healthcare options more accessible to patients TORONTO & DETROIT–(BUSINESS WIRE)– Few days matter more to your health than those immediately following a brain cancer diagnosis. Initial treatment decisions have a direct and significant impact on your ability …...

Ipsen Announces Data Presentations of Cabozantinib (Cabometyx™), Lanreotide (Somatuline® Autogel®) and Telotristat Ethyl* at the European Society for Medical Oncology (ESMO) 2016 Congress

Tuesday, September 27th 2016 at 4:00pm UTC PARIS–(BUSINESS WIRE)– class= »bwalignl »> Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced that Cabometyx™ (cabozantinib), Somatuline® Autogel® (lanreotide) and telotristat ethyl (*previously known as telotristat etiprate) will be the subject of 16 ...


Quick Search
Advertisement